MarketCap
Facebook
X
Telegram
Omnicell Book Value | OMCL
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Omnicell
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.23 B | 1.24 B | 1.19 B | 1.13 B | 1.15 B | 968 M | 845 M | 680 M | 517 M | 432 M | 402 M | 390 M | 349 M | 308 M | 283 M | 265 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.24 B | 265 M | 711 M |
Quarterly Book Value Omnicell
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 B | 1.26 B | 1.22 B | 1.26 B | 1.26 B | 1.24 B | 1.23 B | 1.2 B | 1.19 B | 1.19 B | 1.19 B | 1.16 B | 1.14 B | 1.13 B | 1.14 B | 1.09 B | 1.07 B | 1.15 B | 1.11 B | 1.05 B | 1.01 B | 968 M | 968 M | 968 M | 968 M | 845 M | 845 M | 845 M | 845 M | 680 M | 680 M | 680 M | 680 M | 554 M | 554 M | 554 M | 554 M | 432 M | 432 M | 432 M | 432 M | 402 M | 402 M | 402 M | 402 M | 390 M | 390 M | 390 M | 390 M | 349 M | 349 M | 349 M | 349 M | 308 M | 308 M | 308 M | 308 M | 283 M | 283 M | 283 M | 283 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 B | 283 M | 745 M |
Book Value of other stocks in the Health information services industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Teladoc Health
TDOC
|
1.39 B | $ 6.26 | 0.24 % | $ 1.1 B |  USA |
 |
10x Genomics
TXG
|
796 M | $ 65.6 | 4.71 % | $ 8.18 B | USA |
 |
Veeva Systems
VEEV
|
7.21 B | $ 264.84 | 1.3 % | $ 43.3 B | USA |
 |
Zhongchao
ZCMD
|
22.6 M | $ 0.85 | 0.29 % | $ 2.91 M |  China |
 |
Cerner Corporation
CERN
|
3.68 B | - | - | $ 27.9 B | USA |
 |
Change Healthcare
CHNG
|
3.28 B | - | - | $ 9.03 B | USA |
 |
Covetrus
CVET
|
1.53 B | - | - | $ 2.94 B | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
804 M | - | -10.39 % | $ 886 M | USA |
 |
NantHealth
NH
|
-225 M | - | -46.64 % | $ 10.4 M | USA |
 |
1Life Healthcare
ONEM
|
1.54 B | - | - | $ 3.37 B | USA |
 |
R1 RCM
RCM
|
347 M | - | - | $ 3.81 B | USA |
 |
Tabula Rasa HealthCare
TRHC
|
-57 M | - | - | $ 255 M | USA |
 |
Signify Health
SGFY
|
821 M | - | -0.02 % | $ 7.21 B | USA |
 |
American Well Corporation
AMWL
|
248 M | $ 13.34 | 2.69 % | $ 214 M | USA |
 |
Castlight Health, Inc.
CSLT
|
7.25 B | - | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
715 M | - | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
26.4 M | - | - | $ 6.37 B | USA |
 |
Evolent Health
EVH
|
415 M | $ 4.22 | 1.41 % | $ 482 M | USA |
 |
GoodRx Holdings
GDRX
|
616 M | $ 3.52 | 1.15 % | $ 1.25 B | USA |
 |
Health Catalyst
HCAT
|
246 M | $ 1.7 | 0.59 % | $ 119 M | USA |
 |
HealthEquity
HQY
|
2.11 B | $ 93.36 | 0.24 % | $ 8.04 B | USA |
 |
HealthStream
HSTM
|
520 M | $ 28.72 | 1.78 % | $ 862 M | USA |
 |
So-Young International
SY
|
1.67 B | $ 2.65 | 0.18 % | $ 206 M | China |
 |
iCAD
ICAD
|
28.7 M | - | - | $ 102 M | USA |
 |
OptimizeRx Corporation
OPRX
|
128 M | $ 7.6 | 1.74 % | $ 141 M | USA |
 |
Progyny
PGNY
|
516 M | $ 27.15 | 4.66 % | $ 2.31 B | USA |
 |
Phreesia
PHR
|
337 M | $ 10.22 | 0.76 % | $ 611 M | USA |
 |
NextGen Healthcare
NXGN
|
400 M | - | - | $ 1.6 B | USA |
 |
Accolade
ACCD
|
445 M | - | 0.29 % | $ 206 M | USA |
 |
Computer Programs and Systems
CPSI
|
178 M | - | 4.4 % | $ 133 M | USA |
 |
Akerna Corp.
KERN
|
666 M | - | - | $ 161 M | USA |
 |
MTBC
MTBC
|
59.5 M | - | -0.58 % | $ 51.7 M | USA |
 |
Premier
PINC
|
1.53 B | - | - | $ 2.33 B | USA |
 |
Schrödinger
SDGR
|
364 M | $ 20.03 | 0.2 % | $ 1.47 B | USA |
 |
Streamline Health Solutions
STRM
|
12.3 M | - | - | $ 21.4 M | USA |
 |
SCWorx Corp.
WORX
|
7.15 M | - | - | $ 7.71 M | USA |